Former drug executive Martin Shkreli, who last year became a lightning rod for outrage over soaring prescription drug prices, may face additional U.S. charges of securities fraud, a federal prosecutor said on Tuesday. More charges related to Shkreli's involvement with biopharmaceutical company Retrophin Inc could be filed within a month, Assistant U.S. Attorney Winston Paes said at a hearing in federal court in Brooklyn, New York. Shkreli, 33, sparked outrage among patients, medical societies and U.S. lawmakers after another company he ran, Turing Pharmaceuticals, raised the price of the drug Daraprim by more than 5,000 percent to $750 a pill.
After a month of often violent protests, French lawmakers on Tuesday started to debate a hotly contested labor bill that would make it easier to lay off workers, weaken some union powers, and relax rules ...
LILLINGTON, N.C. (AP) — A jail inmate who was backing away from an officer was shocked with a stun gun three times and left alone for about 20 minutes in a padded cell where he died, according to a video released to a North Carolina newspaper.
DES MOINES, Iowa (AP) — In a story May 2 about the Marine Corps investigating whether it misidentified one of the men in the iconic photo of men raising the U.S. flag at Iwo Jima in 1945, The Associated Press erroneously reported that two amateur historians contend that a figure initially identified as John Bradley was actually Harold Henry Schultz. They argue that the figure identified as Franklin Sousley was actually Schultz and the figure initially identified as Bradley was Sousley, which would mean Bradley wasn't in the photo.